2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3424 Real-world outcomes with revumenib across diverse molecular subtypes and treatment settings in acute myeloid leukemia: A single-center experience

Umar Iqbal, MD, MBBS, Onyee Chan, MD2, Rory Shallis, MD3, Lorena Lopez-Gonzalez, PhD4, Syeda Saba Kareem, PharmD5, Alison Walker, MD6, Craig Freyer, PharmD, BCOP7, Andrew T Kuykendall, MD8, Huan Huang, PhD9, Zhuoer Xie, MD,MS10, Eric Padron, MD11, Rami Komrokji, MD12, Jeffrey Lancet, MD13, David Sallman, MD14
1 Moffitt Cancer Center, Tampa, United States
2 Moffitt Cancer Center, Tampa, United States
3 Moffitt Cancer Center, Tampa, United States
4 Syndax Pharmaceuticals, Inc, New York, United States
5 Moffitt Cancer Center, Tampa, United States
6 Moffitt Cancer Center, Tampa, United States
7 Syndax Pharmaceuticals, Inc, New York, United States
8 Moffitt Cancer Center, Tampa, United States
9 Syndax Pharmaceuticals, Inc, New York, United States
10 Moffitt Cancer Center, Tampa, United States
11 Moffitt Cancer Center, Tampa, United States
12 Moffitt Cancer Center, Tampa, United States
13 Moffitt Cancer Center, Tampa, United States
14 Moffitt Cancer Center, Tampa, United States

Background:Revumenib, an oral, potent, and selective inhibitor of the menin-KMT2A interaction, is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an NPM1 mutation (NPM1m) or KMT2A-rearrangement (KMT2Ar). Here, we report our expanded real-world institutional experience with revumenib, including patients (pts) across additional molecular subgroups, clinical settings (MRD positive disease and post-HSCT maintenance), and combination treatment strategies.

Methods: Pts who received >1 dose of revumenib between December 2024 and June 2026 outside of a clinical trial were identified from institutional prescription data. Pts were followed from revumenib initiation until data cutoff (09Jul2026) or death. Clinical responses in frontline and relapsed/refractory (R/R) patients were assessed according to the 2022 ELN criteria. Composite complete remission (CRc) was defined as CR+CRh+CRi. The overall response rate (ORR) was defined as CRc+MLFS+PR. Response in patients treated solely for MRD-positive disease was assessed by conversion to MRD negativity. Grade ≥3 (G3) non-hematological treatment-related adverse events were captured.

Results: 32 pts were included (AML, n=31; CML-BP, n=1) with a median follow-up of 8.3 mo (range, 0.4–28.1). Genotypes included KMT2Ar in 14 pts (44%), NPM1m in 11 (34%), NUP98r in 5 (16%), and PICALM::MLLT10 in 1 (3%).1 pt with a false-positive KMT2Ar was included only in safety analyses. Median age was 62 years (range, 24–82); 23 pts (72%) were white and 20 (63%) were male. Median number of prior lines of therapy was 2 (range, 0–5). Twenty-three pts (72%) had prior venetoclax exposure (57% for KMT2Ar; 100% for NPM1m). Ten pts (31%) had received a prior HSCT (14% for KMT2Ar and 45% for NPM1m).Pts were treated for R/R disease (n=23, 72%), MRD+ disease (n=5, 16%), in frontline setting (n=3, 9%) and only as post-HSCT maintenance in 1 (3%). Combination therapy was common (n=23, 72%), most often with venetoclax and/or hypomethylating agent (18/23).

 Of the 32 treated pts, 30 were efficacy evaluable. Overall, 70%(21/30) of pts achieved a response. Among 23 pts with R/R disease, the ORR was 65%(15/23) and CRc was 48%(11/23). Three patients without response assessment were counted as non-responders. Median (range) time to first and best overall response was 0.9 mo (0.6–6.4) and 4.6 mo (0.7–14.7), respectively. By molecular category, ORR was 70.0% (7/10) in KMT2Ar, 71.4% (5/7) in NPM1m, 40.0% (2/5) in NUP98r, and 100% (1/1) in PICALM::MLLT10 (MLFS). Corresponding CRc rates were 60.0% (6/10), 57.1% (4/7), 20.0% (1/5), and 0% (0/1), respectively. Among responders, relapse occurred in 28.6% (2/7) of KMT2Ar, 40.0% (2/5) of NPM1m, 50.0% (1/2) of NUP98r, and 100% (1/1) of PICALM::MLLT10 patients. For the R/R cohort, the median overall survival (mOS) was 15.0 months (95% CI, 8.2 months–not reached [NR]). mOS for NPM1m cohort was 15.0 months (95% CI, 7.7 months- NR) and mOS could not be estimated for KMT2Ar and NUP98r cohorts by end of data cut-off. Among pts treated for MRD+ disease, 80% (4/5) achieved MRD negativity (3 by NPM1 PCR and 1 by flow cytometry in KMT2Ar); 1 pt remained NPM1 PCR-positive. Two responders subsequently relapsed, one with peripheral blood MRD recurrence (NPM1 PCR) at 7.2 months and one with isolated CNS relapse at 1.3 months.

Of 9 pts who proceeded to HSCT, 6/9 received maintenance with a median duration of 8.3 mo (range, 0.3-28), with 3 patients remaining on it at data cutoff. In total, 38% pts (8/21) relapsed after achieving a response (across r/r, MRD+, frontline setting), including 4 with isolated CNS relapse. Of note, among the R/R pts that underwent HSCT, only 1/5 relapsed (isolated CNS, treated and in remission with ongoing maintenance therapy).

From safety perspective, 10 deaths occurred; none were related to revumenib treatment (7 disease progression related, 1 HSCT related, 1 sepsis, 1 metastatic neuroendocrine carcinoma). Regular ECG monitoring was available for 26/32 pts. Five pts had G3 QTcF prolongation (19%; 3 interruptions, 1 reduction) although 2/5 met G3 QTcF criteria only due to a >60 msec increase from baseline. G3 differentiation syndrome occurred in 3 pts (9%; 1 discontinuation).

Conclusion: Revumenib based therapy demonstrated meaningful clinical activity across KMT2Ar, NPM1m, and NUP98r AML with encouraging MRD clearance and favorable post-HSCT outcomes. Isolated CNS relapse emerged as a notable pattern warranting further investigation.

 

Umar Iqbal, MD, MBBS: No relevant conflicts of interest to declare.